corporate site
TENACIOUSLY WORKING
TO FIGHT VIRAL THREATS

Press Releases

October 14, 2026
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
October 5, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
September 29, 2026
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
September 8, 2026
Invivyd to Participate in Upcoming September Investor Conferences
September 3, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
September 1, 2026
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
August 13, 2026
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 4, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
July 6, 2026
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
July 2, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 33
Print
Contact IR
RSS
Email Alerts